# Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update
Ticker: CHRS
Company: Coherus BioSciences, Inc.
Source: Coherus BioSciences, Inc.
Published: 2026-03-09 20:15 EST
Original Source URL: https://investors.coherus.com
## Summary

– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call

## Article Body
– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call
## Recent Company News
- 2026-05-11 20:05 EST — [Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Coherus BioSciences, Inc.
- 2026-05-04 13:30 EST — [Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026) — Source: Coherus BioSciences, Inc.
- 2026-03-09 20:15 EST — [Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update) — Source: Coherus BioSciences, Inc.
- 2026-03-02 14:30 EST — [Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-9-2026) — Source: Coherus BioSciences, Inc.
- 2026-02-23 14:30 EST — [Coherus Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-conferences) — Source: Coherus BioSciences, Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)